Piramal Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
NiveshIQ
NSE: PPLPHARMA · Healthcare
Piramal Pharma Ltd.
₹239.92▲ ₹1.01 (+0.42%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on PPLPHARMA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Piramal Pharma Ltd.
Piramal Pharma Limited (PPLPHARMA) operates as a diversified pharmaceutical company with a global footprint in the United States, Europe, Japan, India, and other international markets. The core business includes manufacturing and marketing of generic and specialty drugs, inhalation anesthetics, intrathecal therapies for spasticity, injectable pain management, and a range of consumer health products such as analgesics, skin care, and supplements. The company also runs a contract development and manufacturing organization (CDMO) that provides end‑to‑end services for vaccines and biologics, contributing a significant portion of its revenue. In FY27 H1, revenue rose 23% to ₹9,205 Cr and EBITDA margin improved by 350 basis points, prompting a revised FY27 revenue outlook of 19%–20%. Recent acqu
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹8,171 Cr +15.39% | ₹9,151 Cr +11.99% | ₹8,869 Cr -3.08% |
| EBITDA Margin | 14.64% | 15.79% | 10.39% |
| Net Profit | ₹17.82 Cr -142.50% | ₹91.13 Cr +411.39% | -457.66% |
| EPS | ₹0.14 | ₹0.69 | ₹-2.46 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Piramal Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Piramal Pharma Ltd Sees Robust Trading Activity Amid Institutional Interest
🔒
+ 3 more stories about Piramal Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q2FY27 results: revenue ₹2, 617 Cr, PAT ₹6 Cr, EPS ₹0.04, EBITDA margin 13.3%. Growth context: revenue YoY +28.1%, revenue QoQ +15.3%, PAT QoQ -108.0%.
Management highlights product launches, approvals, therapy‑mix improvement, new capacity addition and capex deployment a...
FY26 (last completed FY): revenue ₹8, 869 Cr, PAT ₹-326 Cr, EBITDA margin 10.4%, EPS ₹-2.46. Year-on-year: revenue YoY -...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Nephrocare Health Services Ltd.Neuland Laboratories Ltd.Onesource Specialty Pharma Ltd.Orchid Pharma Ltd.Park Medi World Ltd.Pfizer Ltd.Poly Medicure Ltd.Procter & Gamble Health Ltd.Procter & Gamble Hygiene & Health Care Ltd.QMS Medical Allied Services Ltd.Rainbow Childrens Medicare Ltd.Rubicon Research Ltd.
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for PPLPHARMA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track PPLPHARMA alongside your other holdings
Unlock full PPLPHARMA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Piramal Pharma Ltd.?
NiveshIQ detects active intelligence signals for Piramal Pharma Ltd. (PPLPHARMA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Piramal Pharma Ltd.?
Piramal Pharma Ltd. operates in the Healthcare sector with a market capitalisation of ₹2,838,057.1L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.